Permitted Uses BA shall use Protected Information only for the purpose of performing BA’s obligations under the Contract and as permitted or required under the Contract and Addendum, or as required by law. Further, BA shall not use Protected Information in any manner that would constitute a violation of the Privacy Rule or the HITECH Act if so used by CE. However, BA may use Protected Information as necessary (i) for the proper management and administration of BA;
Permitted Use (a) Tenant shall, at all times during the Term, and at any other time that Tenant shall be in possession of any Property, continuously use and operate, or cause to be used and operated, such Property as a skilled nursing/ intermediate care/independent living/assisted living/ special care/group home facility as currently operated, and any uses incidental thereto. Tenant shall not use (and shall not permit any Person to use) any Property, or any portion thereof, for any other use without the prior written consent of Landlord, which approval shall not be unreasonably withheld, delayed or conditioned. No use shall be made or permitted to be made of any Property and no acts shall be done thereon which will cause the cancellation of any insurance policy covering such Property or any part thereof (unless another adequate policy is available) or which would constitute a default under any ground lease affecting such Property, nor shall Tenant sell or otherwise provide to residents or patients therein, or permit to be kept, used or sold in or about any Property any article which may be prohibited by law or by the standard form of fire insurance policies, or any other insurance policies required to be carried hereunder, or fire underwriter’s regulations. Tenant shall, at its sole cost (except as expressly provided in Section 5.1.2(b)), comply or cause to be complied with all Insurance Requirements. Tenant shall not take or omit to take, or permit to be taken or omitted to be taken, any action, the taking or omission of which materially impairs the value or the usefulness of any Property or any part thereof for its Permitted Use.
(b) In the event that, in the reasonable determination of Tenant, it shall no longer be economically practical to operate any Property as currently operated, Tenant shall give Landlord Notice thereof, which Notice shall set forth in reasonable detail the reasons therefor. Thereafter, Landlord and Tenant shall negotiate in good faith to agree on an alternative use for such Property, appropriate adjustments to the Additional Rent and other related matters; provided, however, in no event shall the Minimum Rent be reduced or abated as a result thereof. If Landlord and Tenant fail to agree on an alternative use for such Property within sixty (60) days after commencing negotiations as aforesaid, Tenant may market such Property for sale to a third party. If Tenant receives a bona fide offer (an “Offer”) to purchase such Property from a Person having the financial capacity to implement the terms of such Offer, Tenant shall give Landlord Notice thereof, which Notice shall include a copy of the Offer executed by such third party. In the event that Landlord shall fail to accept or reject such Offer within thirty (30) days after receipt of such Notice, such Offer shall be deemed to be rejected by Landlord. If Landlord shall sell the Property pursuant to such Offer, then, effective as of the date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the net proceeds of sale received by Landlord multiplied by the Interest Rate. If Landlord shall reject (or be deemed to have rejected) such Offer, then, effective as of the proposed date of such sale, this Agreement shall terminate with respect to such Property, and the Minimum Rent shall be reduced by an amount equal to the product of the projected net proceeds determined by reference to such Offer multiplied by the Interest Rate.
Prohibited Uses You may use the Website only for lawful purposes and in accordance with these Terms of Use. You agree not to use the Website: • In any way that violates any applicable federal, state, local, or international law or regulation (including, without limitation, any laws regarding the export of data or software to and from the US or other countries). • For the purpose of exploiting, harming, or attempting to exploit or harm minors in any way by exposing them to inappropriate content, asking for personally identifiable information, or otherwise. • To send, knowingly receive, upload, download, use, or re-use any material that does not comply with the Content Standards set out in these Terms of Use. • To transmit, or procure the sending of, any advertising or promotional material without our prior written consent, including any "junk mail," "chain letter," "spam," or any other similar solicitation. • To impersonate or attempt to impersonate the Company, a Company employee, another user, or any other person or entity (including, without limitation, by using email addresses or screen names associated with any of the foregoing). • To engage in any other conduct that restricts or inhibits anyone's use or enjoyment of the Website, or which, as determined by us, may harm the Company or users of the Website, or expose them to liability. Additionally, you agree not to: • Use the Website in any manner that could disable, overburden, damage, or impair the site or interfere with any other party's use of the Website, including their ability to engage in real time activities through the Website. • Use any robot, spider, or other automatic device, process, or means to access the Website for any purpose, including monitoring or copying any of the material on the Website. • Use any manual process to monitor or copy any of the material on the Website, or for any other purpose not expressly authorized in these Terms of Use, without our prior written consent. • Use any device, software, or routine that interferes with the proper working of the Website. • Introduce any viruses, Trojan horses, worms, logic bombs, or other material that is malicious or technologically harmful. • Attempt to gain unauthorized access to, interfere with, damage, or disrupt any parts of the Website, the server on which the Website is stored, or any server, computer, or database connected to the Website. • Attack the Website via a denial-of-service attack or a distributed denial-of-service attack. • Otherwise attempt to interfere with the proper working of the Website.
Prohibited Use You may not use the Website for any of the following purposes:
Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Clomethiazole (Heminevrin®) PHE Community-based assisted alcohol withdrawal - as per NICE CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prevention of atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care TA210 - Dec 10 Hospital Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Prophylaxis pre-elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Clopidogrel (Plavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Acute Coronary Syndrome without ST- segment elevation (NSTEMI) (with aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month. NICE has not issued any guidance. Hospital Clozapine (Clozaril®, Denzapine®, Zaponex®) ICB Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG82 - Mar 09 Hospital Cobicistat ▼ (Tybost® ▼) NHSE Use as a booster in treatment of HIV positive adults and adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cobimetinib ▼ (in combination with vemurafenib) (Cotellic® ▼) NHSE Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 414 Not commissioned. No NHS prescribing in primary or secondary care TA414 - Oct 16 Hospital Co-careldopa intestinal gel (Duodopa® ▼) NHSE Severe Xxxxxxxxx'x disease inadequately controlled by other preparations - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Cochlear implants (Various) NHSE For children and adults with severe to profound deafness - specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE Management of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Colestipol hydrochloride (Colestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. (Nebulised) Hospital Colistimethate sodium Dry Powder Inhaler (Colobreathe® Dry Powder Inhaler) NHSE Pseudomonas lung infection in cystic fibrosis - as per NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17
